Azole comopund ophthalmic preparation
AssigneesQinyuan ZHENG, Biotool, LLC, Inhibio Bioscience Pte. Ltd.
InventorsQinyuan ZHENG, Zeyidan JIAPAER
Life of this patent
Estimating the term…
Abstract
An ophthalmic pharmaceutical composition containing an azole compound, a method for preparing the same, as well as a use of the pharmaceutical composition in the preparation of an ophthalmic preparation for preventing and treating ophthalmic diseases. The ophthalmic preparation contains the azole compound at a concentration of 0.005-400 μM.
Claims20
A method for preventing or treating an ocular lens disease, which comprises non-invasively administering an ophthalmic preparation to an eye or two eyes of a subject in need thereof;
- the ophthalmic preparation comprises:
- (a) a pharmaceutically acceptable carrier, and (b) an azole compound as a first active ingredient.
A method for preventing or treating human or non-human mammal ocular lens disease, which comprises administering an ophthalmic preparation;
- the ophthalmic preparation comprises:
- (a) a pharmaceutically acceptable carrier, and (b) an azole compound as a first active ingredient.
A method for preventing or treating an ocular lens disease, which comprises the following steps:
- orally administering an oral preparation or administering an injection formulation to the eye(s) of a subject in need thereof, wherein the oral preparation or injection formulation comprises (a1) a pharmaceutically acceptable carrier, and (b1) an azole compound as a first active ingredient;
- wherein the concentration of the azole compound in the preparation is 0.01-90 wt %.
The method of claim 19, wherein the ocular lens disease is selected from the group consisting of:
- cataract, presbyopia, and combinations thereof.
The method of claim 20, wherein the cataract is selected from the group consisting of:
- senile cataract, congenital cataract, traumatic cataract, and concurrent cataract.
Dependencies are inferred from the claim text.